Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: Set the bugs to work?
Drug delivery is a rapidly growing area of research motivated by the nanotechnology
revolution, the ideal of personalized medicine, and the desire to reduce the side effects of …
revolution, the ideal of personalized medicine, and the desire to reduce the side effects of …
Targeting myeloid-derived suppressor cells in cancer
W Anani, MR Shurin - … in Cancer Progression and Cancer Therapy, 2017 - Springer
Myeloid derived suppressor cells (MDSC) represent only a minor fraction of circulating blood
cells but play an important role in tumor formation and progression. They are a …
cells but play an important role in tumor formation and progression. They are a …
Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial
JV Gavilondo, F Hernández-Bernal, M Ayala-Ávila… - Vaccine, 2014 - Elsevier
CIGB-247 is a novel cancer therapeutic vaccine that uses a human VEGF variant molecule
as antigen, in combination with a bacterial adjuvant. In mice, CIGB-247 has anti-tumor and …
as antigen, in combination with a bacterial adjuvant. In mice, CIGB-247 has anti-tumor and …
Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine
Y Morera, J Sánchez, M Bequet-Romero… - Vaccine, 2017 - Elsevier
CIGB-247 is a cancer therapeutic vaccine, based on recombinant modified human vascular
endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a …
endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a …
[HTML][HTML] Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator
L Oliver, R Alvarez, R Diaz, A Valdés… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Immune suppression is common in neoplasia and a major driver is tumor-
induced myeloid dysfunction. Yet, overcoming such myeloid cell defects remains an …
induced myeloid dysfunction. Yet, overcoming such myeloid cell defects remains an …
Vaccination approach to anti-angiogenic treatment of cancer
MQ Wentink, EJM Huijbers, TD de Gruijl… - … et Biophysica Acta (BBA …, 2015 - Elsevier
Improvement of patient survival by anti-angiogenic therapy has proven limited. A vaccination
approach inducing an immune response against the tumor vasculature combines the …
approach inducing an immune response against the tumor vasculature combines the …
Active immunization with a structurally aggregated PD-L1 antigen breaks T and B immune tolerance in non-human primates and exhibits in vivo anti-tumoral effects in …
Y Morera-Díaz, C Canaán-Haden, J Sánchez-Ramírez… - Cancer letters, 2023 - Elsevier
Despite the clinical success of the programmed death ligand 1 (PD-L1) blocking therapy in
cancer treatment, only a subset of patients exhibits durable responses, therefore further …
cancer treatment, only a subset of patients exhibits durable responses, therefore further …
Xanthium strumarium s xanthatins induces mitotic arrest and apoptosis in CT26WT colon carcinoma cells
J Piloto-Ferrer, A Sanchez-Lamar, M Francisco… - Phytomedicine, 2019 - Elsevier
Background Colorectal cancer is one of the most common malignancies worldwide and is
associated with high mortality rates. We previously reported that Xanthium strumarium L …
associated with high mortality rates. We previously reported that Xanthium strumarium L …
Vaccines targeting angiogenesis in melanoma
F Zahedipour, P Zamani, K Jamialahmadi… - European Journal of …, 2021 - Elsevier
Angiogenesis has a significant role in metastasis and progression of melanoma. Even small
tumors may be susceptible to metastasis and hence lead to a worse outcome in patients with …
tumors may be susceptible to metastasis and hence lead to a worse outcome in patients with …
[HTML][HTML] IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic …
S Kanekiyo, S Hazama, H Takenouchi… - Oncology …, 2018 - spandidos-publications.com
Cancer vaccines have been developed as a new therapeutic approach, however, their
clinical benefit remains limited. We previously performed a phase II study for advanced …
clinical benefit remains limited. We previously performed a phase II study for advanced …